Estimated Incidence of Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus Infections Among Adults in Germany Between 2015 and 2019.

Autor: Polkowska-Kramek A; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium., Begier E; Pfizer Inc, Dublin, Ireland., Bruyndonckx R; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium., Liang C; Pfizer Inc, 66 Hudson Blvd E, New York, NY, 10001, USA. caihua.liang@pfizer.com., Beese C; Pfizer Pharma GmbH, Berlin, Germany., Brestrich G; Pfizer Pharma GmbH, Berlin, Germany., Tran TMP; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium., Nuttens C; Pfizer Inc, Paris, France., Casas M; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium., Bayer LJ; Pfizer Pharma GmbH, Berlin, Germany., Huebbe B; Pfizer Pharma GmbH, Berlin, Germany., Ewnetu WB; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium., Agudelo JLR; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium., Gessner BD; Pfizer Inc, 66 Hudson Blvd E, New York, NY, 10001, USA., von Eiff C; Pfizer Pharma GmbH, Berlin, Germany., Rohde G; Medical Clinic I, Department of Respiratory Medicine, Goethe University Frankfurt, University Hospital, Frankfurt/Main, Germany.
Jazyk: angličtina
Zdroj: Infectious diseases and therapy [Infect Dis Ther] 2024 Apr; Vol. 13 (4), pp. 845-860. Date of Electronic Publication: 2024 Mar 23.
DOI: 10.1007/s40121-024-00951-0
Abstrakt: Introduction: Respiratory syncytial virus (RSV) burden in adults is underestimated mainly due to unspecific symptoms and limited standard-of-care testing. We estimated the population-based incidence of hospitalization and mortality attributable to RSV among adults with and without risk factors in Germany.
Methods: Weekly counts of hospitalizations and deaths for respiratory, cardiovascular, and cardiorespiratory diseases were obtained (Statutory Health Insurance database, 2015-2019). A quasi-Poisson regression model was fitted to estimate the number of hospitalizations and deaths attributable to RSV as a function of periodic and aperiodic time trends, and viral activity while allowing for potential overdispersion. Weekly counts of RSV and influenza hospitalizations in children < 2 years and adults ≥ 60 years, respectively, were used as viral activity indicators. Models were stratified by age group and risk status (defined as presence of selected comorbidities).
Results: Population-based RSV-attributable hospitalization incidence rates were high among adults ≥ 60 years: respiratory hospitalizations (236-363 per 100,000 person-years) and cardiorespiratory hospitalizations (584-912 per 100,000 person-years). RSV accounted for 2-3% of all cardiorespiratory hospitalizations in this age group. The increase in cardiorespiratory hospitalization risk associated with underlying risk factors was greater in 18-44 year old persons (five to sixfold higher) than in ≥ 75 year old persons (two to threefold higher).
Conclusions: This is a first model-based study to comprehensively assess adult RSV burden in Germany. Estimated cardiorespiratory RSV hospitalization rates increased with age and were substantially higher in people with risk factors compared to those without risk factors. Our study indicates that RSV, like other respiratory viruses, contributes to both respiratory and cardiovascular hospitalizations. Effective prevention strategies are needed, especially among older adults ≥ 60 years and among adults with underlying risk factors.
(© 2024. Pfizer.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje